Prednisolone inhibits endotoxin-induced disseminated intravascular coagulation and improves mortality in rats: Importance of inflammatory cytokine suppression

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 6, 1999, Pages 321-330

  Yamazaki, Masahide ^a,b   Aoshima, K ^a   Mizutani, T ^a   Ontachi, Y ^a   Saito, M ^a   Morishita, E ^a   Asakura, H ^a   Matsuda, T ^a   Triplett, D A ^b  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

^b BALL MEMORIAL HOSPITAL   (United States)

Author keywords

Disseminated intravascular coagulation; Heparin; Inflammatory cytokine; Mortality; Organ failure; Prednisolone

Indexed keywords

ALANINE; ANTITHROMBIN III; CREATINE; CYTOKINE; ENDOTOXIN; HEPARIN; HEPARIN SODIUM INJECTION USP; INTERLEUKIN 1BETA; INTERLEUKIN 6; PREDNINE; PREDNISOLONE; THROMBIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIABETES MELLITUS; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOGEN METABOLISM; HEMOSTASIS; HUMAN; MALE; MORTALITY; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; STEROID THERAPY; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT;

EID: 0032880340     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199909000-00002     Document Type: Article

References (32)

1. 1. Asakura H, Jokaji H, Saito H, Uotani C, Kumabashiri I, Morishita E, et al. Changes in plasma levels of tissue-plasminogen activator/inhibitor complex and active plasminogen activator inhibitor in patients with disseminated intravascular coagulation. Am J Haematol 1991; 36: 176-183.
2. 2. Muller-Berghaus GM, Hasegawa H. Pathogenesis of disseminated intravascular coagulation. In: Abe T, Yamanaka M (editors): Disseminated intravascular coagulation. Tokyo: University of Tokyo Press; 1981. pp. 3-13.
3. 3. Levi M, Ten Cate H, Van der Poll T, Van Deventer SJH. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270: 975-979.
4. 4. Van der Poll T, Buller HR, Ten Cate H, Wortel CH, Bauer KA, Van Deventer SJH, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622-1627.
5. 5. Jansen PM, Boermeester MA, Fischer E, De Jong IW, Van der Poll T, Moldawer LL, et al. Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis: Studies in nonhuman primates after interleukin-1a administration and during lethal bacteremia. Blood 1995; 86: 1027-1034.
6. 6. Jacqueline M, Stouthard L, Levi M, Hack CE, Veenhof CH, Romijn HA, et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76: 738-742.
7. 7. Wakabayashi T, Kitajima M. Anti-cytokine strategies - modulation of systemic inflammatory response syndrome by IL-1 receptor antagonist and soluble TNF receptor [in Japanese]. J Clin Exp Med 1994; 169: 850-855.
8. 8. Yamazaki M, Asakura H, Aoshima K, Saito M, Jokaji H, Uotani C, et al. Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats. Thromb Haemost 1994; 72: 393-396.
9. 9. Quick AJ, Stanly-Brown M, Bancroft FW. A study of the coagulation defect in hemophilia and in jaundice. Am J Med Sci 1935; 190: 501-511.
10. 10. Goodwin JF. Estimation of plasma fibrin using sodium sulfate fractionation. Am J Clin Pathol 1961; 35: 227-232.
11. 11. Ferreia HC, Murat LG. Immunological method for demonstrating fibrin degradation products in serum and its use in the diagnosis of fibrinolytic states. Br J Haematol 1963; 9: 299-310.
12. 12. Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in human plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101-106.
13. 13. Yamazaki M, Asakura H, Aoshima K, Saito M, Jokaji H, Uotani C, et al. Protective effects of DX-9065a, an orally active, novel synthesized and selective inhibitor of factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats. Semin Thromb Hemost 1996; 22: 255-259.
14. 14. Komatsu Y, Saika K, Ogura K, Yamanaka S, Nishimori Y, Shimasaki M, et al. Evaluation of ready-to-use, liquid type reagent for creatinine assay "L-type Wako Creatinine F" [in Japanese]. J Clin Lab Inst Reag 1996; 19: 807-813.
15. 15. Bergmeyer HU, Scheibe P, Wahlefeld AW. Optimization of methods for aspartate aminotransferase and alanone aminotransferase. Clin Chem 1978; 24: 58-73.
16. 16. Yamazaki M, Asakura H, Aoshima K, Saito M, Matsuda T, Triplett DA. Prednisolone inhibits endotoxin-induced disseminated intravascular coagulation and improves mortality in rats: importance of inflammatory cytokine suppression. Blood 1997; 90 (suppl): 103b.
17. 17. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 1987; 330: 662-664.
18. 18. Eisenberg SP, Evans RJ, Arend WP, Verderber E, Brewer MT, Hannum CH, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 antagonist. Nature 1990; 343: 341-346.
19. 19. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA. A specific antagonist for interleukin a prevents Escherichia coli-induced shock in rabbits. FASEB J 1991; 5: 338-343.
20. 20. Fischer E, Marano MA, Van Zee KJ, Rock CS, Hawes AS, Thompson WA, et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to after host responses to sublethal endotoxemia. J Clin Invest 1992; 89: 1551-1557.
21. 21. Mancilla J, Garcia P, Dinarello CA. The interleukin-1 receptor antagonist can either reduce or enhance the lethality of Klebsiella pneumoniae sepsis in newborn rats. Infect Immunol 1993; 61: 926-932.
22. 22. Wakabayashi G, Gelfand JA, Jung WK, Connolly RJ, Burke JF, Dinarello CA. Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli. J Clin Invest 1991; 87: 1925-1935.
23. 23. Beulter B, Krochin N, Milsark IW, Luedke C, Cerami A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 1986; 232: 977-980.
24. 24. Knudsen PJ, Dinarello CA, Strom TB. Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin-1 in U937 cells. J Immunol 1987; 139: 4129-4134.
25. 25. Lee W, Oppenheim JJ, Matsushima K. Glucocorticoids selectively inhibit the transcription of the interleukin-1β mRNA. J Immunol 1988; 140: 1204-1208.
26. 26. Bone RC, Risher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317: 653.
27. 27. Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Narray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988; 62: 138.
28. 28. Sprung CL, Caralis PV, Marcial EH, Pierce M, Gelbard MA, Long WM, et al. The effects of high-dose corticosteroids in patients with septic shock: a prospective, controlled study. N Engl J Med 1994; 311: 1137.
29. 29. Murakami K, Okajima K, Mitsuhiro U, Johno M, Okabe H, Takatsuki K. A novel platelet activating factor antagonist, SM-12502, attenuates endotoxin-induced disseminated intravascular coagulation and acute pulmonary vascular injury by inhibiting TNF production in rats. Thromb Haemost 1996; 75: 965-970.
30. 30. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Endotoxin-induced pulmonary vascular injury is mainly mediated by activated neutrophils in rats. Thromb Res 1995; 78: 117-125.
31. 31. Danielsson A, Raub E, Lindahl U, Bjork I. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 1986; 261: 15467-15473.
32. 32. Ten Cate JW, Van der Poll T, Levi M, Ten Cate H, Van Deventer SJH. Cytokines: triggers of clinical thrombotic disease. Thromb Haemost 1997; 78: 415-419.